Patients treated with chemotherapy or immunosuppressives are at higher risk of influenza infection and mortality and morbidity are higher compared to healthy adults. Vaccination against the influenza virus can prevent these complications. In this study it is investigated whether vaccination during chemotherapy is effective in reaching protective serum antibody concentrations and the relation between time of vaccination (day 4 +/- 1 day versus day 16 +/- 1 day of the chemotherapy cycle).

Start Date01 Oct 2009

Sponsor / Collaborator

St.-Antonius-Hospital gGmbH

100 Clinical Results associated with Influenza virus vaccine(Crucell Holdings, Inc.)

100 Translational Medicine associated with Influenza virus vaccine(Crucell Holdings, Inc.)

100 Patents (Medical) associated with Influenza virus vaccine(Crucell Holdings, Inc.)

Literatures (Medical) associated with Influenza virus vaccine(Crucell Holdings, Inc.)

31 Dec 2024·Human Vaccines & Immunotherapeutics

Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies

Article

Author: Shi, Hua ; Freiden, Pam ; Zhang, Xiaojian ; Ross, Ted M ; Livingston, Brandi ; Schultz-Cherry, Stacey ; Meliopoulos, Victoria ; Ge, Pan

The influenza viruses cause seasonal respiratory illness that affect millions of people globally every year. Prophylactic vaccines are the recommended method to prevent the breakout of influenza epidemics. One of the current commercial influenza vaccines consists of inactivated viruses that are selected months prior to the start of a new influenza season. In many seasons, the vaccine effectiveness (VE) of these vaccines can be relatively low. Therefore, there is an urgent need to develop an improved, more universal influenza vaccine (UIV) that can provide broad protection against various drifted strains in all age groups. To meet this need, the computationally optimized broadly reactive antigen (COBRA) methodology was developed to design a hemagglutinin (HA) molecule as a new influenza vaccine. In this study, COBRA HA-based inactivated influenza viruses (IIV) expressing the COBRA HA from H1 or H3 influenza viruses were developed and characterized for the elicitation of immediate and long-term protective immunity in both immunologically naïve or influenza pre-immune animal models. These results were compared to animals vaccinated with IIV vaccines expressing wild-type H1 or H3 HA proteins (WT-IIV). The COBRA-IIV elicited long-lasting broadly reactive antibodies that had hemagglutination-inhibition (HAI) activity against drifted influenza variants.

01 Oct 2024·International Journal of Infectious Diseases

Vaccine-related influenza virus B infection in a child with an undiagnosed B-cell acute lymphoblastic leukemia

Article

Author: Biffi, Alessandra ; Conciatori, Valeria ; Salata, Cristiano ; Franchin, Elisa ; Sopra, Sarah Di ; Lavezzo, Enrico ; Pietra, Giuseppe Di ; Vecchio, Claudia Del ; Castagliuolo, Ignazio ; Petris, Maria Grazia

We report a case of Influenza type B (lineage Yamagata) infection in a child who received the live attenuated influenza virus vaccine before being diagnosed with B-cell acute lymphoblastic leukemia. The patient developed a mild disease that persisted for 18 days and resolved without antiviral treatment. The prolonged infection of an attenuated virus in an immunocompromised host might pose a risk of reversion or evolution to a more pathogenic strain. Prompt prevention, identification, and monitoring of similar cases are desirable to avoid the development of severe illness, which could complicate patient management.

01 Oct 2024·Vaccine

A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters

Article

Author: Tompkins, S. Mark ; Loganathan, Madhumathi ; Clark, Jordan J. ; Krammer, Florian ; Kawaoka, Yoshihiro ; Vasilev, Kirill ; Neumann, Gabriele ; Tompkins, S Mark ; Gu, Chunyang ; Guan, Lizheng ; Campbell, John D. ; Clark, Jordan J ; Fan, Shufang ; Francis, Benjamin ; Hoxie, Irene ; Campbell, John D ; Yu, Dong ; Bushfield, Kaitlyn

Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.

100 Deals associated with Influenza virus vaccine(Crucell Holdings, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 2	-	Crucell Holdings, Inc.	-
Influenza, Human	Phase 2	-	Novavax, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Influenza virus vaccine(Crucell Holdings, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation